Essentials of COVID-19 and treatment approaches
Data Science for COVID-19: Volume 2: Societal and Medical Perspectives
; : 397-422, 2021.
Article
in English
| Scopus | ID: covidwho-1872866
ABSTRACT
The coronavirus family is as old as the 1930s when it first showed symptoms in chicken. The virus thereafter kept evolving and it has significantly taken over a large percentage of people worldwide in the form of this new pandemic. As of the present day, there is no treatment available for coronavirus disease 2019 (COVID-19) (caused by the severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]), although supportive therapy and preventive measures have shown a tremendous control rate among certain patients. Drugs like remdesivir, camostat, nafamostat, ritonavir/lopinavir, several monoclonal antibodies, and CPs are in their early phases of trials. There are approved by the WHO under an emergency use authorization program. Favipiravir has entered its phase 3 clinical trial and is supported by evidence to show no or less adverse effects in patients infected with SARS-CoV-2. Vaccine development is accelerating its pace, and vaccines will probably become available by the end of the year 2020. © 2022 Elsevier Inc.
Full text:
Available
Collection:
Databases of international organizations
Database:
Scopus
Language:
English
Journal:
Data Science for COVID-19: Volume 2: Societal and Medical Perspectives
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS